Protein Restriction and Endometriosis: What the Evidence Actually Supports

A new longevity review has revived an old question — does eating less protein quiet the biology that drives endometriosis? The mechanism is real. The evidence is thinner than it looks, and one part of it points the other way.

By Andrea Vidali, MD · Reviewed by Dr. Fernandez and Dr. Raccuia

Endometriosis Surgical Specialists International (ESSI), New York / New Jersey

The Short Answer

There is no clinical evidence that a low-protein diet improves endometriosis. The mechanism is plausible—protein restriction suppresses mTORC1, which is overactive in endometriotic lesions—but it has been tested only in flies, mice, and a 21-person, 27-day metabolic trial.

For women with endometriosis, we advise attention to protein quality, source, and distribution rather than reduction—and higher protein intake, not lower, around surgery and during pregnancy.

The Shared Upstream Signaling Node

• Core Pathway: Lowering dietary protein / essential amino acids $\rightarrow$ mTORC1 decreased, AMPK increased, FGF21 increased (the shared upstream node).

• Claimed Benefits: Improved insulin sensitivity, decreased cellular senescence, improved mitochondrial function, and extended lifespan in flies and mice.

• Unweighed Costs: AVPV kisspeptin suppression (blunting ovulation), loss of lean mass and impaired wound healing, lifespan benefits that skew male in mice, and potential induction of autophagy that lesions may use as a survival mechanism.

A Paper One Week Old

On July 31, 2026, Cell Press Blue published a review by Knopf and Lamming drawing on more than 350 studies evaluating what happens when dietary protein is reduced. The authors defined six hallmarks of protein restriction:

1. Improved metabolic health

2. Induction of nutrient-sensing pathways

3. Decreased cellular senescence

4. Improved mitochondrial function

5. An altered epigenome

6. Promotion of healthy aging

They singled out three specific branched-chain amino acids—methionine, isoleucine, and valine—as carrying much of the biological effect.

It is a well-designed review. It is also brand new, unreplicated, uncommented-on, and built almost entirely on Drosophila, rodents, and a small number of short human trials. The word endometriosis does not appear in it once.

We are writing about it because the pathway at its center (mTOR) is one we have debated in reproductive medicine for a decade—and because patients are already being told that this paper holds therapeutic promises for their pelvic pain.

First, a Correction the Field Still Has Not Absorbed

Endometriosis is not misplaced endometrium. This is not a semantic preference. A 2025 review in eLife revealed that almost half of publicly available datasets labeled “endometriosis” are actually built on eutopic endometrium (the lining of the uterus) rather than on true ectopic lesion tissue. Sweeping conclusions have been drawn about a disease from samples that are not the disease.

Endometriotic lesions differ from eutopic endometrium in five critical ways:

• Cellular Composition: Epithelial populations are significantly reduced; stromal cells are increased.

• Behavior: Lesion cells adhere, migrate, and invade more aggressively, exhibiting elevated epithelial-to-mesenchymal transition (EMT).

• Gene Expression: Coordinated shifts toward chronic inflammatory activation, collagen formation, and extracellular matrix degradation.

• Mode of Cell Death: Healthy endometrial cells undergo routine apoptosis and autophagy. Lesion cells are far more resistant and tend to undergo pyroptosis and ferroptosis—highly inflammatory modes of cell death.

• Metabolism: Lesions sit in chronic hypoxia and oxidative stress, exhibiting metabolic reprogramming similar to the Warburg effect seen in tumors.

The mTOR Node, and the Limits of Shared-Node Reasoning

Endometriotic lesions express higher levels of phosphorylated mTOR than normal uterine tissue. That hyperactivation is associated with four primary clinical drivers: cell proliferation, angiogenesis, progesterone resistance, and tissue inflammation. Protein restriction suppresses mTORC1. So does rapamycin. The pathway is genuinely shared.

However, two major caveats prevent this mechanism from translating into dietary advice:

1. mTOR Is Not One Single Molecule: Low, acute exposure to rapamycin selectively inhibits mTORC1. Sustained, long-term exposure also inhibits mTORC2. mTORC2 inhibition causes glucose intolerance and insulin resistance—the exact opposite of the advertised metabolic benefits. Writing “mTOR” without specifying the complex obscures a critical biological divergence.

2. Sharing a Node Does Not Equal Clinical Benefit: Endometriotic tissue is an independent pathology. Just because lesions and aging fibroblasts both run hot on mTORC1, a low-protein diet studied in fruit flies cannot be assumed to shrink a rectovaginal nodule in a woman. Sharing an upstream signaling node is a reason to form a hypothesis, not a reason to prescribe a diet.

The Translational Ladder: Where Evidence Actually Sits

ESSI Editorial Standard: Any claim drawn from Rungs 01–04 must explicitly name the species, sample size, and study duration in the same sentence as the claim.

FGF21 Cuts Both Ways: The Omitted Reproductive Cost

The hormone doing much of the metabolic heavy lifting during protein restriction is Fibroblast Growth Factor 21 (FGF21), a hepatokine released by the liver when amino acid intake drops. FGF21 increases energy expenditure, improves glycemic control, and dampens systemic inflammation.

However, FGF21 is also the primary signal by which a mammal tells its brain that it is starving and should shut down reproduction.

Research published in Nature Medicine demonstrated that FGF21 acts on the suprachiasmatic nucleus to suppress vasopressin, which subsequently suppresses kisspeptin, blunting the pro-oestrus surge in luteinising hormone (LH). Female transgenic mice overexpressing FGF21 were infertile, showing disturbed estrous cycles and significantly fewer corpora lutea. The affected kisspeptin population—located in the anteroventral periventricular (AVPV) nucleus—exists in females, not in males.

This aligns with a crucial detail from the Cell Press Blue review itself: the lifespan benefit of elevated FGF21 was significantly more pronounced in male mice than in female mice.

• Metabolic Arm (Reported): Energy expenditure $\uparrow$, improved glycemic control, inflammation $\downarrow$, lifespan $\uparrow$ in mice with elevated FGF21 (rises in humans on low-protein intake; effect on lifespan was more pronounced in male mice).

• Reproductive Arm (Omitted): FGF21 acts on the suprachiasmatic nucleus to suppress vasopressin $\rightarrow$ kisspeptin signaling, blunting the pro-oestrus LH surge. Transgenic female mice are infertile with disturbed cycles and fewer corpora lutea. The affected AVPV kisspeptin population is female-specific. This represents an adaptive starvation response, not a minor side effect.

Recommending severe protein restriction to a readership of reproductive-age women—many of whom are actively trying to conceive—ignores an established starvation signal that directly suppresses female ovulation.

The Autophagy Contradiction

Suppressing mTORC1 induces autophagy—the catabolic process where cells recycle damaged organelles and proteins. In longevity literature, autophagy is celebrated as “cellular cleanup”.

In endometriosis biology, the role of autophagy is a double-edged sword:

1. Premise 1: Protein restriction suppresses mTORC1.

2. Premise 2: mTORC1 suppression induces autophagy.

3. The Conflict: Endometriotic cells actively use autophagy as a survival mechanism to tolerate the hypoxic, high-iron, and inflammatory environment of the peritoneal cavity.

4. Unstated Consequence: Mildly inducing autophagy through dietary restriction may inadvertently support lesion survival and persistence rather than clearing disease.

While sustained, high-dose pharmacologic mTOR inhibition (e.g., high-dose rapamycin) can tip lesion cells past survival into apoptosis, the mild, intermittent autophagic signal triggered by a low-protein diet may do the exact opposite by helping ectopic cells endure metabolic stress.

The Carnivore Diet: Why Elimination Works (and Why Protein Doesn’t)

Many women in endometriosis support groups report feeling better on a carnivore diet—noting reductions in pain, severe bloating (“endo belly”), and bowel dysfunction. They are not imagining this improvement.

However, the relief comes from what the diet eliminates, not from the high intake of red meat:

The Better Alternative: Patients do not need to choose between severe protein restriction and an all-meat diet. The most constructive approach is a low-FODMAP, plant-forward, omega-3-rich Mediterranean pattern. This maintains gut elimination benefits without over-activating mTORC1 or causing dyslipidemia.

“If I Eat Less Protein, Won’t I Eat More Carbohydrates?”

A 2022 randomized trial in Nutrients evaluated 21 adults with metabolic syndrome over 27 days. They compared isocaloric protein restriction against overall calorie restriction:

• Calorie Restriction Group: Insulin sensitivity improved by 62.3%.

• Protein Restriction Group: Insulin sensitivity improved by 93.2%, and HbA1c fell despite an increased intake of carbohydrates.

While intriguing, this pilot study involved only 21 total participants, lasted less than a month, and was conducted under strict inpatient supervision where both groups lost weight. A 21-person short-term trial in metabolic syndrome cannot justify broad dietary changes for women with pelvic endometriosis.

The Terrain Is Not the Lesion

Dietary changes alter the terrain—the metabolic and inflammatory environment surrounding pelvic organs. Modifying the terrain is valuable: it can reduce central pain sensitization, improve bowel/bladder symptoms, and decrease systemic fatigue.

However, diet does not remove anatomical lesions. No dietary pattern can excise a deep rectovaginal nodule, release an obliterated pouch of Douglas, or clear ureteral obstruction.

Laparoscopic excision surgery remains the definitive treatment for physical disease, while targeted nutrition serves as a supportive adjunct—never a substitute. Postponing necessary surgery to experiment with extreme diets carries real risks of disease progression and organ damage.

What ESSI Actually Advises

We do not recommend reducing overall protein intake. Instead, we recommend optimizing protein quality, sources, and timing:

• Protein Source: Shift toward legumes, tofu, tempeh, and fatty fish. These have lower branched-chain amino acid concentrations, are higher in fiber, and deliver anti-inflammatory omega-3s. This is a change in composition, not a reduction in quantity.

• Distribution: Spread protein intake across the day rather than loading a single meal. Nutrient-sensing pathways respond to high single-meal peaks rather than daily totals.

• Surgery Window: In the 8 weeks before and after excision surgery, protein intake should be maintained or increased, not reduced. Protein restriction during the perioperative period depletes lean muscle mass, impairs wound healing, and compromises immune recovery.

Do NOT Restrict Protein If You Fall Into Any of These Categories

• You are pregnant, trying to conceive, or undergoing active fertility treatment.

• You are within 8 weeks before or after planned surgery.

• You have iron-deficiency anemia or low baseline ferritin.

• You have a low BMI or a history of disordered eating.

• You are an adolescent.

• You are taking a GLP-1 receptor agonist (e.g., semaglutide, tirzepatide).

• You have chronic kidney disease or sarcopenia (reduced muscle mass).

Warning for GLP-1 Users: Lean muscle loss is a well-documented adverse effect of GLP-1 therapy. Restricting protein while taking a GLP-1 agonist accelerates muscle wasting and metabolic slowing.

Emerging Therapies We Are Tracking

• Low-Dose Rapamycin: A retrospective cohort of 168 women with endometriosis evaluated 3 months of low-dose rapamycin prior to a second IVF cycle, reporting lower follicular fluid oxidative stress and improved fertilization, implantation, and live birth rates. While hypothesis-generating, rapamycin is an immunosuppressant and remains investigational.

• NLRP3 Inflammasome Inhibitors: Estrogen-driven inflammasome activation represents a promising parallel axis to mTOR in pelvic disease. Clinical trials are still in early stages.

• GLP-1 Receptor Agonists: GLP-1 agents demonstrate direct anti-inflammatory pathways across pelvic tissue, which we address in a separate clinical review.

Frequently Asked Questions

Does eating less protein help endometriosis?

No clinical trials have evaluated protein restriction in human endometriosis. The theory relies on animal models and small metabolic studies. Reducing protein carries risks to fertility and surgical recovery.

How much protein should I eat if I have endometriosis?

Eat a standard, balanced intake aligned with your activity level, focusing on high-quality plant proteins and fatty fish. Do not restrict protein, and increase intake around surgery or during pregnancy.

Is the carnivore diet recommended for endometriosis?

No. While eliminating ultra-processed foods and gluten can reduce gut symptoms, the high protein and saturated fat load strongly activates the mTORC1 growth pathway, while the lack of fiber harms gut microbiome diversity.

What is mTOR, and why does it matter in endometriosis?

mTOR (mechanistic target of rapamycin) is a cell-growth signaling pathway that is overactive in endometriotic lesions. While quieting mTOR is a logical therapeutic goal, restricting dietary protein is an unproven and potentially harmful way to target it.

Can rapamycin cure endometriosis?

No. Rapamycin is an experimental immunosuppressive drug. While early pilot data in IVF cohorts show interest, it is not an approved or standard treatment for endometriosis.

References

1. Knopf BA, Lamming DW. The hallmarks of protein and amino acid restriction in aging and longevity. Cell Press Blue. 2026. doi:10.1016/j.cpblue.2026.100079.

2. Gunther K, Fisher T, Liu D, Abbott J, Ford CE. Endometriosis is not the endometrium: reviewing the over-representation of eutopic endometrium in endometriosis research. eLife. 2025;14:e103825. doi:10.7554/eLife.103825.

3. Dietary protein restriction improves metabolic dysfunction in patients with metabolic syndrome in a randomized, controlled trial. Nutrients. 2022;14(13):2670. doi:10.3390/nu14132670.

4. Owen BM, Bookout AL, Ding X, et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat Med. 2013;19(9):1153–1156. doi:10.1038/nm.3250.

5. Singhal G, et al. Fibroblast growth factor 21 has no direct role in regulating fertility in female mice. Mol Metab. 2016;5(8):690–698.

6. Protein-restricted diets and their impact on metabolic health and aging. Annu Rev Nutr. 2026. doi:10.1146/annurev-nutr-121624-114918.

7. A cohort study on IVF outcomes in infertile endometriosis patients: the effects of rapamycin treatment. Reprod Biomed Online. 2023. PMID:37914557.

MEDICAL DISCLAIMER: This article is strictly educational and does not constitute medical advice, diagnosis, or treatment. Do not alter your diet, supplements, or medical care without consulting your physician. Off-label therapies discussed (such as rapamycin or GLP-1 agents) are not approved for endometriosis.